Corporate Office : Mahendra Industrial Estate,

Aarti Drugs Limited

Manufacturerc of : Bulk Drugs & Chemicals

Ground Floor, Plot No. 109-D, Road No. 29,

Sion (East), Mumbai - 4OO 022. (India)
Tel.:022-2407 2249 | 2401 9025 (30 Lines)
Fax.:022-2407 3462 I 2407 0144
Email : admin@aartidrugs.com
website: www.aaftidrugs.com
CIN No. : |jf 7060MH1984P1C055433

Ref: ADL/SE/2016-17

Date:5s May,20L6
To,
Department of Corporate Services
BSE Limited
Phiroze f eeieebhoy Towers,

Dalal Sheet,
Mumbai - 400 001
BSE CODE - 524348
BSE ID - AARTIDRUGS

National Stock Exchange of India

Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra(E), Mumbai - 400 051
NSE CODE: AARTIDRUGS

sub: outcome of Board Meeting held today i.e. sth May, 20L6 pursuant to
Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III
of SEBI (Listing Obligations & Disclosure Requirements) Regulations,20L5
Dear Sir,

Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule

III of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we
inform you that the Board of Directors at its Meeting held today i.e. Thursday, Sft
May, 2016 had inter-alla considered and approved the Audited Financial Results
(Standalone & Consolidated) for the Quarter and Year ended 31't March, 20'1.6.
Accordingly, please find enclosed herewith the following:

L. Statement of Audited Financial Results

(Standalone & Consolidated) for the

Quarter and Year ended on 31"t March, 201.6 alongwith report of the Statutory
Auditors and

2.

Form A of Audit Report with unmodified opinion

Kindly take the same on your records and acknowledge receipt.

Thanking you,
Yours faithfullv,
For Aarti Drugs Limit

{6
vib
Company Secretary & Compliance Officer
Encl: ArlA

'Corporate Office :

Mahendra Industrial Estate,

Plot No. 109-D, Road No. 29, Sion (East),

Mumbai - 4O0 022. (India)

Tel.:022-2407 2249

| 24019025 (30 Lines)

Fax: 022-2407 3462 / 2407 0144

Email : admin@aartidrugs.com

Aarti Drugs Limited

Website : www.aaftidrugs.com
CIN NO : 137060MH1984P1C055433

Manufacturers of : Bulk Drugs & Chemicals

AARTI DRUGS LIMITED

3lST MARCH' 2016
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ANo YEAR ENDED
consolidated

sb

oaPT I

Particulars

31stMar2ol6

(Auditeo

2,681

29,695
51

2
(a) Cost of materials consumed
(b) Purchase of stock-in-trade
(c) Changes in inventories of finished goods'
work-irFprogress and stock'in-trade
(d) Employee benelils exPense
(e) Depreciation and Amonisation Expense
(f) Other expenses

Total expenses
Profit from Operations before Othor Income'

Expenses

1(

Provision forTilatiOn - Cunent

- MAT Credit Entitlement
- Eadier Year
Provision for Defened Taxalion
(e-10)
11 Net profit from ordinary Activities after Tax
aordinary items
1i
,|:
(1'l+121
Prcfitforthe Period

31st Mar 2o1 5

(Audited)

3'1st Mar 20'16

30,067
2,300
27,761

1,'16,610

1,16,994
8,546
1,08,/H8

33,975

3'l st Ma r 201 5

lAudited)

(Audited)

32,376

31st Mar 20'16

(Audited)

31stOec2015

27,619
2,322
25,297

9,530
1,07,073

J/5

A7A

274

550

109.722

31st Mar 20'|6

31st Mar 2015

(Auditd)

(Audited)

(Audited)

'r,17,960
8,533
1,09,427

1,22,A31

31,397

28,799
2,299
26,499

31.461

26.867

15,281
1,101

72,102
5,060

8,721

1,140

(4el)

(2,730

098

4,476

922

3,653

3,793
3,102
13.983
95.888

I,v2

1,13,488
4C6

25.672

27.837

16,235
514
r R5l

14,799
ooc
1,109

15,630
1,192
2,139

68,298
3,652
(525)

67,444

16,704

a,721

'1,464
3,52,3

1t9

1,O17

1 024

907
3 q52

809
24 355

4,136
3,558
l/t 818
oa o?a

3,730
3,066

26.279

900
3 829
22,319

3,466

3,353

3,482

13,612

3.466

3,353

3,482

1,125

1,117

2,U1
2 341

3lst Dec 2015

2,575

29,746

-O7

Yeat Enqeq

ouarter Ended

Year Ended

Ouader Ended

(2,358)

1,22',1

.13.984

1_O9

6aA

69,019

935
3.974
27.A21

3 923
23 465

3,640

3,402

13,9't6

13,612

13,829
65
13,894

3,640

3,402

13,9'16

13,800
65
13,865

o7a

4,328

3,888

1,'151

1,124

4,389

3,893

2,236

2,506

9,2U

10,006

2,449

2,274

9,527

9,972

2236

2 506

92e/

10.006

2 4Ag

2 278

9,527

9.972

ozu
528

2,655

OJU

575

2 655

435

490

:u

21_'15

2,247
2,100
(100
(153

3 56t

la

Anq

94 493

15 ?AC

O0

068

140

1An

540

2,247
2,100
(100'
(1 53
400

,oo

140

540

/tOO

1.71'l

't 661

1.886

6.629

7.760

1.859

r 703

6.572

7.725

1.71'l

661

'I 886

6.629

76{J

1.859

703

6872

7.725

'1.7'11

1.661

1 886

o.ozv

7.760

1.859

't 703

6.A72

7.725

2422

2,422

2A22

2,422
32.6't0

2,422

2,422

2,422

2,422

2,422
28.394

630

To

2,115

(48)

't40

of Profiu (Loss) of associates

lnterest

1/

l!

Profit for the Pariod aftel taxes, minority lnterest

share of proflu (loss) of associates

Paid-up Equity Share Capital of Rs.10f each.

Reserves & Surplus (excluding revaluation reserues)
Eaming per share

,|

33,318

27,945

DilutedEPS(inRs.)
Rs, 10 /- each) (not annualised)
|

items)
(bl Basic & Diluted ( after exlraordinary items)

Plaer Mumbal
Date: sth May,2015

707
7.O7

646
686

779

3204

/Y

32.O4

2838

76

HARSHIT M. SAVIA
JT. MANAGING DIRECTOR

7.03

28.38

3t
3t

Corporate Office : Mahendra Industrial Estate,

Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Plot No. 109-D, Road No. 29, Sion (East),

Mumbai - 400 022. (India)
Tel.:022-2407 2249 | 2401 9025 (30 Lines)
Fax:022-2407 3462 | 2407 Ol44
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : 137060MH1984P1C055433

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2016 ( RS. iN IACS)

Consolidated
Stand alone
Particulars
31st Mar 20',16

31st Mar 2015

31st Mar20'16

31st Mar 2015

EQUITY AND LIABILITIES

1

Shareholde/ funds
(a) Share Capital
(b) Reserves and surplus

2,422
32,610

Total - Shareholders's funds

2 Non-current liabilities
(a) Long - term borrowings
(b) Deferred tax liabilities (net)
(c) Other long - term liabilities
(d) Long - term provisions
Total - Non - current liabilities
3 Current

35,031

2,422
27,949
30,370

17,521
4,041

15,147
3,501

19j23

16,347

4,042

1,027

1,205
29
19,883

1,071
142

3,502
1,225
29
21,'tO3

142
22,731

33,318
35,740

2,422
28,394
30,81s

2,422

24,378

liabilities

(a) Short - term borrowings

(b) Trade payables
(c) Other current liabilities
(d) Short - term provisions

Total

25,737

current liabilities

TOTAL- EQUITY AND LIABILITIES

25,127
15,019

25,841

16,418

4,224
1,328

4,119
2,176

4,380

47,708

50,102

1.05.470

46,440
96.693

49,681

44,483

18,490

25,243
16,672
4,153

2,208

1,391

.10.22Q

48,276
1 .00.194

424
46,019

52,746
463
488
53,697

46,452
463
724
47,640

17,835

3,94s
54,203

15,336
30,759
343
1,745
2,491
50,674

33,169
482
1,924
3,113
56,522

16,420
31,427
358
1,76s
2,585

1.05.470

96.693

1.10.220

ASSETS

B
1

Non-current assets
(a) Fixed assets ( including CWIP)
(b) Non - current investments
(c) Long - term loans and advances
Total - Non - current assets

Current assets
(a) Inventories
(b) Trade receivables
(c) Cash and cash equivalents
(d) Short - term loans and advances
(e) Other -Current assets

Total

current assets

TOTAL - ASSETS

1,112
474
51,267

16,705
32,120
450
1,884

1,111

52,5U
1.00.194

Notes :
1 The above results for the Quarter and Year ended 31st March, 2016 have been reviewed by the Audit Committee and approved by
the Board of Directors in their meeting held on Sth May, 2016.

2 The company has published consolidated financial Results from Quarter Ended September,2015 in addition to stand alone Results,
pursuance to decision taken by Board of Director in its Meeting held on july 31 ,2015, As a results the audited Financial Results of its
only subsidiary , Pinnacle Life science Pvt. Ltd., for the Quarter Ended December 31 ,,2015 and March 31,2016 has been included.

3 Company is operating as a single segment company, engaged in pharmaceutical Business.

Figures for the previous period have been regrouped or rearranged wherever necessary.

5 The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available
on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit
ofthe shareholders and investors.

For
Place: Mumbai
-= Date:sth May,2015

LIMITED

HARSHIT M. SAVIA
JT. MANAGING DIRECTOR

Corporate Office : Mahendra Industrial Estate,

Aarti Drugs Limited

Manufacturerc of : Bulk Drugs & Chemicals

Ground Floor, Plot No. 109-D, Road No. 29,

Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.:022-2407 3462 | 2407 Ot44
Email : admin@aartidrugs.com
website : www.aartidrugs. com
CIN No. : L!7060MH 1984P1C055433

FORM A
(For audit report with unmodified opinion)

[Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 20151
Name of the Company
Annual Financial Statement for the year
ended
Type of Audit Observation
Frequency of Observation

1.
2.
a
J.

Aarti Drugs Limited

March 37, 201,6 [Standalone]

Un-Modified
Not Applicable

For Gokhale & Sathe

Chartered Accountants
Regn No.103264W

Chairman, Managing Director & CEO

Tejas Parikh
Partner
Membership No.1232L5

[DIN:00005618]

.-)

(-,

v-->

_;"_<a\

Ramdas M. Gandhi
Chairman of Audit Committee

[DIN:00029a3n

eY

fl Hlurulant

Adhish P. Patil
Chief Financial Officer [CFO]

gokhale B sathe
(regd.)
chartered accountants
308/309, udyog mandir no 1,
7-c, bhagoji keer marg,
mahim. mumbai 400 016

and Year to Date Results of

Auditor,s Report on Quarterly Financial Results

AARTIDRUGSLIMITEDPursuanttotheRegulation33oftheSEBI(Listing
2015
OUfigutions and Disclosure Requirements) Regulations'

To

ihe eoard of Directors of AARTI DRUGS LIMITED

DRUGS LIMITED
we have audited the quarterly financial results of AARTI

('the

and the year to date financial results for

company,) for the quarter ended March 3l,2016
herewith' being submitted by the
the period from April l,20l5to March 3l,20l6,attached
33 of the sEBI (Listing obligations
company pursuant to the requirement of Regulation
2015' These quarterly financial results as well
and Disclosure Requirements) Regulations,
financial
have been prepared on the basis of the interim
as the year to date financial results
the company's management' Our responsibility
statements, which are the responsibility of
based on our audit of such interim
is to express an opinion on these financial results
in accordance with the recognition and
financial statements, which have been prepared
(AS) 25' on Interim Financial
principles laid down in Accounting Standard
measurement

the
companies Act,2013 read with Rule 7 of
Reporting, specified under section 133 of the
accounting principles generally accepted in
companies (Accounts) Rules, 2014 andother

India.

we conducted our audit in accordance with the auditing

standards generally accepted in

plan and perform the audit to obtain reasonable

India. Those standards require that we
audit
are free of material misstatement(s). An
assurance about whether the financial results
the amounts disclosed as financial
includes examining, on a test basis, evidence supporting
accounting principles used and significant
results. An audit also includes assessing the
audit provides a reasonable basis for
made by management. We believe that our
estimates

our opinion.

gokhale B sathe
(regd.)

chartered accountants

In our opinion and to the best of our information and according to the explanations given to
us these quarterly financial results as

(i)

well

as the year

to date financial results:

are presented in accordance with the requirements of Regulation 33 of the SEBI

(Listing Obligations and Disclosure Requirements) Regulations, 2015 in this

regard; and

(iD

give a true and fair view of the net profit and other financial information for the
quarter ended March 31, 2016 and year

April l,

2015 to March 31,2016.

For GOKHALE & SATHE

CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

CA TEJAS PARIKH
PARTNER
M. No. 123215
Mumbai,
Dated: May 5, 2016.

to date results for the period from

Corporate Office : Mahendra Industrial Estate,

=D

4-

Aarti Drugs Limited

Manufacturerc of : Bulk Drugs & Chemicals

Ground Floor, Plot No. 109-D, Road No. 29,

Sion (East), Mumbai - 400 022. (India)
Tel.:022-2407 2249 / 240t 9025 (30 Lines)
Fax.:022-2407 3162 | 2107 0t44
Email : admin@aartidrugs.com
website : www.aartidru gs.com
CIN No. : 137060MH 1984P1C055433

FORM A
(For audit report with unmodified opinion)

[Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 20151
1.
2.

J.
4.

Name of the Company

Arrnual Financial Statement for the year
ended
Type of Audit Observation
Frequency of Observation

Aarti Drugs Limited

March 37, 2076 [Consolidated]
Un-Modified
Not Applicable

For Gokhale & Sathe

Chartered Accountants

Prakash M. Patil
Chairman, Managing Director & CEO
[DIN:0000561.8]

Partner
Membership No.1232\5

.4-..
llamdas M. Gandhi
Chairman of Audit Committee
[DIN: 0002943\

Chief Financial Officer [CFO]

gokhale

Cd

sathe
(regd.)

chartered accoulttants
308/309, udyog mandir no 1,
7-c, bhagoji keer marg,
mahim, mumbai 400 016

Auditorts Report on Quarterly Consolidated Financial Results and Year to Date

Consolidated Financial Results of AARTI DRUGS LIMITED Pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015

To
Board

of

Directors of AARTI DRUGS LIMITED.

We have audited the quarterly consolidated financial results of AARTI DRUGS LIMITED
("the Company") for the quarter ended March 31,2016, and the year to date consolidated
financial results for the period from April I,2015 to March 31,2016 attached herewith,
being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 20l5.These quarterly
consolidated financial results as well as the year to date consolidated financial results have
been prepared from consolidated interim financial statements, which are the responsibility
of the Company's management. Our responsibility is to express an opinion on these
consolidated financial results based on our audit of such consolidated interim financial
statements, which have been prepared in accordance with the recognition and measurement
principles laid down in Accounting Standard (AS) 25, on Interim Financial Reporting,
specified under section 133 of the Companies Act,20l3 read with Rule 7 of the Companies
(Accounts) Rules, 2014 and other accounting principles generally acoepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in
India. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial results are free of material misstatement(s). An audit
includes examining, on a test basis, evidence supporting the amounts disclosed as financial
results. An audit also includes assessing the accounting principles used and signifrcant
estimates made by management. We believe that our audit provides a reasonable basis for
our opinion.

We did not audit financial statements/financial information of one subsidiary whose

financial statement/financial information reflect total assets of Rs. 6,693.90 lakhs as at
March 3I,2016 and total revenues of Rs.2,549.56 lakhs and Rs 8,584.07 lakhs for the
quarter and year ended March 31, 2016 respectively as considered in the consolidated
financial statements. These financial statements/ financial information have been audited
by other auditor whose report have been furnished to us and our opinion on the
consolidated financial statements, in so far as it relates to the amounts and disclosures

gokhale

sathe
(regd.)

chartered accountants

In our opinion and to the best of our information and according to the explanations given to
us these quarterly consolidated financial results as well as the year to date consolidated
financial results:

(D
(iD
(iiD

include the quarterly financial results and year to date financial results of its only
subsidiary, Pinnacle Life Science Private Limited
have been presented in accordance with the requirements of Regulation 33 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this
regard; and
give a true and fair view of the consolidated net profit and other financial
information for the quarter ended March 31,2016 and year to date consolidated
results for the period from

For GOKHALE & SATIIE

CHARTERED ACCOUNTANTS
Firm Registration No.: 103264W

M. No. 123215
Place: Mumbai
Date: May 5,2016.

April 1,2015 to March 31,2016.